China"s homegrown anti-cancer drug wins internationalstaff wristbands recognitionEssence Music Festival Relocated To Houston One part grimy dive bar and one part hip live music venue, Off Broadway walks a thin line. The St. Louis venue isn"t so ghetto and grungy that it scares off well known out-of-town groups, and it"s not so pristine and sterile that it seems awkward to watch a local garage band play there on a Wednesday. For those who live in or near St. Louis and have developed a taste for punk, indie rock and Stag, Off Broadway may be the best music venue around.
BEIJING -- China"s homegrown drug Sintilimab designed for treating relapsed or refractory classic Hodgkin lymphoma has won international recognition, with its clinical trial research published as the cover paper in the January issue of The Lancet Haematology.
Hodgkin lymphoma is a rare malignant lymphoma that occurs mostly in young people between the ages of 20 and 40. Although the cure rate of early treatment is high, patients have a 20 percent chance of recurrence after their first treatment. Patients with relapsed or refractory classic Hodgkin lymphoma lack effective treatment in China.
Sintilimab, an anti-PD-1 drug, is a kind of checkpoint inhibitor, an emerging anti-cancer therapeutic modality that boosts the immune system to help the body target and kill tumors.
Professor Shi Yuankai from the Cancer Hospital, Chinese Academy of Medical Sciences, led the clinical research, which enrolled 96 patients with relapsed or refractory classic Hodgkin"s lymphoma from 18 hospitals in China.
Results showed that Sintilimab has favorable activity and acceptable toxicity in Chinese patients with relapsed or refractory classical Hodgkin lymphoma, with 80.4 percent of the patients showing an objective response.
Stephen M Ansell from the Division of Hematology at the Mayo Clinic commented that Sintilimab is a "highly effective treatment which potentially improves the outcomes of patients with classical Hodgkin lymphoma worldwide."
Sintilimab was approved for market authorization by China"s National Medical Products Administration in December 2018.
"The approval will bring more treatment options for cancer patients in China," Shi said.silicone bracelets cheap cool wristbands customize silicone bracelets plastic wristbands uk custom wrist sweatbands